Cargando…

Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review

Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of advanced human malignancies. ICIs-related adverse events, including pancreatitis and diabetes, have been individually characterized in the literature. The co-occurrence of ICIs-related pancreatitis with diabetes is r...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Wei, Gao, Yang, Shi, Xiaoyan, Zhang, Xiaoran, Zhou, Shan, Zhu, Hongxia, Yan, Wei, Wang, Huanping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569069/
https://www.ncbi.nlm.nih.gov/pubmed/37841238
http://dx.doi.org/10.3389/fimmu.2023.1243773
_version_ 1785119488473038848
author Fang, Wei
Gao, Yang
Shi, Xiaoyan
Zhang, Xiaoran
Zhou, Shan
Zhu, Hongxia
Yan, Wei
Wang, Huanping
author_facet Fang, Wei
Gao, Yang
Shi, Xiaoyan
Zhang, Xiaoran
Zhou, Shan
Zhu, Hongxia
Yan, Wei
Wang, Huanping
author_sort Fang, Wei
collection PubMed
description Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of advanced human malignancies. ICIs-related adverse events, including pancreatitis and diabetes, have been individually characterized in the literature. The co-occurrence of ICIs-related pancreatitis with diabetes is rare and easily overlooked, but it is often severe or fatal. We present a patient with renal tumor resection who was treated with injection of the PD-L1 inhibitor toripalimab and eventually developed acute pancreatitis and fulminant type 1 diabetes mellitus. In addition, we conducted a literature review of ICIs-related pancreatitis with diabetes. The case in our report presented with paroxysmal abdominal pain and loss of appetite. Intravenous fluids and insulin infusion improved the patient’s pancreatitis and explosive hyperglycemia. This article suggests that ICIs can affect endocrine and exocrine functions of the pancreas, while providing information and new perspectives for the diagnosis and treatment of this challenging rare disease, helping inspire clinicians for the early identification and effective management of similar cases.
format Online
Article
Text
id pubmed-10569069
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105690692023-10-13 Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review Fang, Wei Gao, Yang Shi, Xiaoyan Zhang, Xiaoran Zhou, Shan Zhu, Hongxia Yan, Wei Wang, Huanping Front Immunol Immunology Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of advanced human malignancies. ICIs-related adverse events, including pancreatitis and diabetes, have been individually characterized in the literature. The co-occurrence of ICIs-related pancreatitis with diabetes is rare and easily overlooked, but it is often severe or fatal. We present a patient with renal tumor resection who was treated with injection of the PD-L1 inhibitor toripalimab and eventually developed acute pancreatitis and fulminant type 1 diabetes mellitus. In addition, we conducted a literature review of ICIs-related pancreatitis with diabetes. The case in our report presented with paroxysmal abdominal pain and loss of appetite. Intravenous fluids and insulin infusion improved the patient’s pancreatitis and explosive hyperglycemia. This article suggests that ICIs can affect endocrine and exocrine functions of the pancreas, while providing information and new perspectives for the diagnosis and treatment of this challenging rare disease, helping inspire clinicians for the early identification and effective management of similar cases. Frontiers Media S.A. 2023-09-28 /pmc/articles/PMC10569069/ /pubmed/37841238 http://dx.doi.org/10.3389/fimmu.2023.1243773 Text en Copyright © 2023 Fang, Gao, Shi, Zhang, Zhou, Zhu, Yan and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Fang, Wei
Gao, Yang
Shi, Xiaoyan
Zhang, Xiaoran
Zhou, Shan
Zhu, Hongxia
Yan, Wei
Wang, Huanping
Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
title Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
title_full Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
title_fullStr Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
title_full_unstemmed Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
title_short Immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
title_sort immune checkpoint inhibitors-related pancreatitis with fulminant type 1 diabetes mellitus: case report and literature review
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569069/
https://www.ncbi.nlm.nih.gov/pubmed/37841238
http://dx.doi.org/10.3389/fimmu.2023.1243773
work_keys_str_mv AT fangwei immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview
AT gaoyang immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview
AT shixiaoyan immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview
AT zhangxiaoran immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview
AT zhoushan immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview
AT zhuhongxia immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview
AT yanwei immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview
AT wanghuanping immunecheckpointinhibitorsrelatedpancreatitiswithfulminanttype1diabetesmellituscasereportandliteraturereview